GYRE THERAPEUTICS INC (GYRE) Fundamental Analysis & Valuation

NASDAQ:GYRE • US4037831033

Current stock price

8.1 USD
+0.2 (+2.53%)
At close:
8.1 USD
0 (0%)
After Hours:

This GYRE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GYRE Profitability Analysis

1.1 Basic Checks

  • GYRE had positive earnings in the past year.
  • GYRE had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: GYRE reported negative net income in multiple years.
  • In multiple years GYRE reported negative operating cash flow during the last 5 years.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M -80M

1.2 Ratios

  • GYRE's Return On Assets of 3.03% is amongst the best of the industry. GYRE outperforms 89.15% of its industry peers.
  • GYRE has a better Return On Equity (4.74%) than 90.50% of its industry peers.
  • GYRE has a Return On Invested Capital of 5.65%. This is amongst the best in the industry. GYRE outperforms 90.89% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GYRE is significantly below the industry average of 27.73%.
  • The 3 year average ROIC (10.43%) for GYRE is well above the current ROIC(5.65%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 3.03%
ROE 4.74%
ROIC 5.65%
ROA(3y)-22.36%
ROA(5y)-50.79%
ROE(3y)-55.67%
ROE(5y)-90.4%
ROIC(3y)10.43%
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • GYRE's Profit Margin of 4.31% is amongst the best of the industry. GYRE outperforms 88.76% of its industry peers.
  • GYRE has a Operating Margin of 9.85%. This is amongst the best in the industry. GYRE outperforms 90.12% of its industry peers.
  • With an excellent Gross Margin value of 95.35%, GYRE belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
  • GYRE's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.85%
PM (TTM) 4.31%
GM 95.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y11.12%
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GYRE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so GYRE is still creating some value.
  • Compared to 1 year ago, GYRE has more shares outstanding
  • GYRE has more shares outstanding than it did 5 years ago.
  • GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 8.19 indicates that GYRE is not in any danger for bankruptcy at the moment.
  • GYRE has a Altman-Z score of 8.19. This is in the better half of the industry: GYRE outperforms 78.68% of its industry peers.
  • GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.19
ROIC/WACC0.62
WACC9.13%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • GYRE has a Current Ratio of 5.60. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 5.60, GYRE perfoms like the industry average, outperforming 59.11% of the companies in the same industry.
  • GYRE has a Quick Ratio of 5.04. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
  • GYRE's Quick ratio of 5.04 is in line compared to the rest of the industry. GYRE outperforms 56.01% of its industry peers.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.04
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GYRE Growth Analysis

3.1 Past

  • The earnings per share for GYRE have decreased strongly by -60.74% in the last year.
  • The Revenue has grown by 10.24% in the past year. This is quite good.
  • Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 40.96% on average per year.
EPS 1Y (TTM)-60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4447.83%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y428.46%
Revenue growth 5Y40.96%
Sales Q2Q%33.45%

3.2 Future

  • Based on estimates for the next years, GYRE will show a very strong growth in Earnings Per Share. The EPS will grow by 39.13% on average per year.
  • Based on estimates for the next years, GYRE will show a very strong growth in Revenue. The Revenue will grow by 22.61% on average per year.
EPS Next Y-281.33%
EPS Next 2Y-76.21%
EPS Next 3Y122.35%
EPS Next 5Y39.13%
Revenue Next Year19.33%
Revenue Next 2Y7.48%
Revenue Next 3Y57.22%
Revenue Next 5Y22.61%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

3

4. GYRE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 45.00 indicates a quite expensive valuation of GYRE.
  • Compared to the rest of the industry, the Price/Earnings ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 90.89% of the companies listed in the same industry.
  • GYRE is valuated expensively when we compare the Price/Earnings ratio to 27.87, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for GYRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 45
Fwd PE N/A
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GYRE is valued cheaper than 90.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 46.78
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • The decent profitability rating of GYRE may justify a higher PE ratio.
  • A more expensive valuation may be justified as GYRE's earnings are expected to grow with 122.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-76.21%
EPS Next 3Y122.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GYRE Dividend Analysis

5.1 Amount

  • No dividends for GYRE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GYRE Fundamentals: All Metrics, Ratios and Statistics

GYRE THERAPEUTICS INC

NASDAQ:GYRE (4/17/2026, 8:18:24 PM)

After market: 8.1 0 (0%)

8.1

+0.2 (+2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-08
Inst Owners3.69%
Inst Owner Change0%
Ins Owners7%
Ins Owner Change0%
Market Cap739.61M
Revenue(TTM)116.59M
Net Income(TTM)5.03M
Analysts84.44
Price Target19.04 (135.06%)
Short Float %12.56%
Short Ratio14.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)90.29%
Min EPS beat(2)-13.5%
Max EPS beat(2)194.08%
EPS beat(4)1
Avg EPS beat(4)35.99%
Min EPS beat(4)-34.64%
Max EPS beat(4)194.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.05%
Min Revenue beat(2)-9.01%
Max Revenue beat(2)2.9%
Revenue beat(4)1
Avg Revenue beat(4)-11.19%
Min Revenue beat(4)-23.85%
Max Revenue beat(4)2.9%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.7%
PT rev (3m)3.7%
EPS NQ rev (1m)-191.66%
EPS NQ rev (3m)-197.77%
EPS NY rev (1m)-271.43%
EPS NY rev (3m)-271.43%
Revenue NQ rev (1m)-8.65%
Revenue NQ rev (3m)-8.65%
Revenue NY rev (1m)-6.23%
Revenue NY rev (3m)-6.23%
Valuation
Industry RankSector Rank
PE 45
Fwd PE N/A
P/S 6.34
P/FCF N/A
P/OCF 732.29
P/B 6.98
P/tB 7.41
EV/EBITDA 46.78
EPS(TTM)0.18
EY2.22%
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.14%
SpS1.28
BVpS1.16
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.16863 (-73.23%)
Profitability
Industry RankSector Rank
ROA 3.03%
ROE 4.74%
ROCE 7.77%
ROIC 5.65%
ROICexc 8.76%
ROICexgc 9.36%
OM 9.85%
PM (TTM) 4.31%
GM 95.35%
FCFM N/A
ROA(3y)-22.36%
ROA(5y)-50.79%
ROE(3y)-55.67%
ROE(5y)-90.4%
ROIC(3y)10.43%
ROIC(5y)N/A
ROICexc(3y)15.29%
ROICexc(5y)N/A
ROICexgc(3y)15.53%
ROICexgc(5y)N/A
ROCE(3y)14.34%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y11.12%
F-Score4
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 77.51%
Cap/Sales 1.65%
Interest Coverage 250
Cash Conversion 7.23%
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.04
Altman-Z 8.19
F-Score4
WACC9.13%
ROIC/WACC0.62
Cap/Depr(3y)359.63%
Cap/Depr(5y)269.11%
Cap/Sales(3y)4.06%
Cap/Sales(5y)4.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4447.83%
EPS Next Y-281.33%
EPS Next 2Y-76.21%
EPS Next 3Y122.35%
EPS Next 5Y39.13%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y428.46%
Revenue growth 5Y40.96%
Sales Q2Q%33.45%
Revenue Next Year19.33%
Revenue Next 2Y7.48%
Revenue Next 3Y57.22%
Revenue Next 5Y22.61%
EBIT growth 1Y-29.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-211.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y127.74%
OCF growth 3YN/A
OCF growth 5YN/A

GYRE THERAPEUTICS INC / GYRE Fundamental Analysis FAQ

What is the fundamental rating for GYRE stock?

ChartMill assigns a fundamental rating of 6 / 10 to GYRE.


Can you provide the valuation status for GYRE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 3 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Overvalued.


What is the profitability of GYRE stock?

GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of GYRE THERAPEUTICS INC (GYRE) stock?

The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 45 and the Price/Book (PB) ratio is 6.98.


Can you provide the dividend sustainability for GYRE stock?

The dividend rating of GYRE THERAPEUTICS INC (GYRE) is 0 / 10 and the dividend payout ratio is 0%.